Natera, Inc.
NASDAQ:NTRAMedical - Diagnostics & Research
+$2.23 today
- Market cap
- $41.98B
- Beta
- 1.54
- P/E (TTM)
- -143.0
- EPS (TTM)
- -$1.60
Volume 1.96M
Average 1.41M
NTRA Interest Expense
Cost of servicing the company's debt during the period.
Natera, Inc.NASDAQ: NTRA
Interest Expense · Q2 FY2026 · quarter ended Jun 2026
Interest expense dips below year-ago levels
Q2 FY2026 interest expense of $890K fell 13.5% year over year, behind the +54.2% change in trailing-twelve-month interest expense. Sequentially, it fell 0.2% from the prior quarter. Over 3 fiscal years it compounded at -24.1% a year.
Context
- Interest expense amounted to 0.2% of revenue in FY2025, down 0.5 pp from a year earlier.
- Interest expense increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -13.5% toward the trailing-twelve-month pace of +54.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 4.07M USD
- Year-over-year change
- -61.9%
- 4-year CAGR
- -16.3%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.07M | -61.9% |
| FY2024 | 2024-12-31 | 10.69M | -15.5% |
| FY2023 | 2023-12-31 | 12.64M | +35.6% |
| FY2022 | 2022-12-31 | 9.32M | +12.2% |
| FY2021 | 2021-12-31 | 8.31M | — |
Interest Expense vs competitors
How NTRA compares with its peers on the latest reported figures
- NTRA's LTM Jun 2026 interest expense of $9.97M is the 2nd highest of the 8 companies compared; the peer median is $196K.
- Its year-over-year change of +54.2% is the 3rd highest of 8, against a peer median of -17.6%.
- Interest expense amounts to 0.4% of revenue for NTRA, versus a peer median of 0.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13.8M | +345.2% | +48.6% | 1.7% | |
| LTM Jun 2026 | $9.97M | +54.2% | -24.1% | 0.4% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $2.98M | -0.5% | -7.5% | 0.7% |
| LTM Mar 2026 | $224K | +409.1% | +0.7% | 0.3% | |
| LTM Mar 2026 | $196K | -17.6% | -58.0% | 0.1% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $41K | -92.4% | — | 0.0% |
| LTM Mar 2026 | $7K | -69.6% | -47.2% | 12.3% | |
| LTM Jun 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding NTRA) | $196K | -17.6% | -7.5% | 0.3% | |
Competitors are the stored peer set for NTRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 625.49M | 820.22M | 1.08B | 1.7B | 2.31B |
| Cost of Revenue | 318.42M | 456.26M | 589.83M | 673.75M | 810.63M |
| Gross Profit | 307.07M | 363.97M | 492.74M | 1.02B | 1.5B |
| Gross Margin | 49.1% | 44.4% | 45.5% | 60.3% | 64.8% |
| Research & Development | 264.21M | 316.42M | 320.68M | 404.14M | 624.11M |
| Selling, General & Admin | 511.03M | 588.59M | 618.31M | 841.31M | 1.18B |
| Operating Expenses | 775.24M | 905.01M | 938.99M | 1.25B | 1.81B |
| Depreciation & Amortization | 11.25M | 16.7M | 24.1M | 30.97M | 43.48M |
| EBITDA | (451.54M) | (520.8M) | (397.8M) | (148.08M) | (220.54M) |
| EBITDA Margin | -72.2% | -63.5% | -36.7% | -8.7% | -9.6% |
| Operating Income | (468.17M) | (541.04M) | (446.25M) | (222.29M) | (309.91M) |
| Operating Margin | -74.8% | -66.0% | -41.2% | -13.1% | -13.4% |
| Interest Income | 5.38M | 3.54M | 24.35M | 43.25M | 45.89M |
| Interest Expense | 8.31M | 9.32M | 12.64M | 10.69M | 4.07M |
| Other Income / Expenses | (2.92M) | (5.78M) | 11.72M | 32.56M | 41.82M |
| Income Before Tax | (471.1M) | (546.82M) | (434.53M) | (189.73M) | (268.09M) |
| Pre-Tax Margin | -75.3% | -66.7% | -40.1% | -11.2% | -11.6% |
| Income Tax Expense | 618K | 978K | 271K | 695K | (59.93M) |
| Net Income | (471.72M) | (547.8M) | (434.8M) | (190.43M) | (208.16M) |
| Net Margin | -75.4% | -66.8% | -40.2% | -11.2% | -9.0% |
| EPS (Basic) | (5.21) | (5.57) | (3.78) | (1.53) | (1.52) |
| EPS (Diluted) | (5.21) | (5.57) | (3.78) | (1.53) | (1.52) |
| Weighted Avg Shares | 90.56M | 98.41M | 115M | 124.72M | 136.72M |
| Weighted Avg Shares (Diluted) | 90.56M | 98.41M | 115M | 124.72M | 136.72M |
Natera, Inc.
NASDAQ:NTRA
Intrinsic Alpha fair value
Locked
Current Price
$289.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.